NCT04314752 Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
| NCT ID | NCT04314752 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Davis |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2020-09-01 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2020-09-01 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objectives of the proposed study are to develop and evaluate protocols for ethnic/racial minority-specific research using cancer registry data. In conjunction with the Cancer Registry of Greater California (CRGC), the investigators have developed procedures to identify, recruit, and survey ethnic/racial minority patients with MM. To pilot the study, the investigators aim initially to test the feasibility of this protocol by contacting 400 eligible patients (100 African Americans, 100 Latinos, 100 Asian American/Native Hawaiian/Pacific Islander-AANHPI and 100 non-Hispanic Whites as a comparison group) to conduct a pilot survey through which will ascertain etiological and survival-related factors for MM. Ultimately, the investigators hope the findings from this pilot will yield insight into the best practices for recruiting minorities with MM and serve as the basis for larger population-based studies of MM etiology and survival. The next phase of this study is to expand the study to all 3 California Cancer Registries, including the Greater Bay Area Cancer Registry and the Los Angeles Cancer Surveillance Program and Cancer Registry of Greater California. We will increase the sample size to recruit atleast 1000 participants per racial/ethnic group. We will also request to increase the scope of the study to also continue a survivorship cohort.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with a first primary pathologically confirmed case of Multiple Myeloma within the previous 5 years * At least 21 years of age at the time of diagnosis * Must have been diagnosed in one of the 48 counties in California * Participant must be alive * Identify as one of the following: African American, Latino, Asian American/Native Hawaiian/Pacific Islander, Non-Hispanic White Exclusion Criteria: * People who have not been diagnosed with Multiple Myeloma * Under the age of 21 * Pregnant * Prisoner
Contact & Investigator
Luis Carvajal-Carmona, PhD
PRINCIPAL INVESTIGATOR
University of California, Davis
Frequently Asked Questions
Who can join the NCT04314752 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04314752 currently recruiting?
Yes, NCT04314752 is actively recruiting participants. Contact the research team at lgcarvajal@ucdavis.edu for enrollment information.
Where is the NCT04314752 trial being conducted?
This trial is being conducted at Sacramento, United States.
Who is sponsoring the NCT04314752 clinical trial?
NCT04314752 is sponsored by University of California, Davis. The principal investigator is Luis Carvajal-Carmona, PhD at University of California, Davis. The trial plans to enroll 4,000 participants.